In two HSIL samples, we detected the p.H1047R mutation of PIK3CA, which was shown to be associated with the response to PI3K/AKT/mTOR signaling pathway inhibitors administered to patients with diverse advanced cancers [49]. This evidence concerns the gene MTOR and cancer.